-
Je něco špatně v tomto záznamu ?
Peroneal electrical transcutaneous neuromodulation in the home treatment of the refractory overactive bladder
J. Krhut, M. Rejchrt, M. Slovak, RV. Dvorak, M. Grepl, P. Zvara
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu multicentrická studie, časopisecké články
NLK
ProQuest Central
od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2010-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
- MeSH
- hyperaktivní močový měchýř * farmakoterapie MeSH
- inkontinence moči * MeSH
- lidé MeSH
- močení fyziologie MeSH
- prospektivní studie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
INTRODUCTION AND HYPOTHESIS: The aim of this prospective, open-label, multicenter, noncomparative study was to evaluate the efficacy and safety of peroneal electrical transcutaneous neuromodulation (peroneal eTNM®) using the URIS® neuromodulation system as a home treatment for refractory overactive bladder (OAB). METHODS: The patients were treated with daily peroneal eTNM® for 30 min over a 6-week period. The primary endpoint was defined as the proportion of responders, i.e., participants with ≥ 50% reduction in the average daily sum of severe urgency episodes (defined as "I could not postpone voiding but had to rush to the toilet in order not to wet myself") and urgency incontinence episodes. In addition, bladder diary variables, symptom severity (OAB V8 questionnaire), treatment satisfaction (visual analog scale), and pain perception (visual analog scale) were evaluated at baseline (BL), at week 4 (W4), and at the end of treatment (EoT). Safety evaluations included monitoring of the incidence and severity of adverse events (AEs). Changes in time were analyzed using the nonparametric one-way ANOVA Friedman test for categorical variables and the Wilcoxon rank-sum test for the noncategorical variables. RESULTS: In total, 40 subjects were screened and 29 were included in the full analysis set. The proportion of responders was 86% at W4 and 79% at EoT. There was a significant reduction in frequency (p<0.001), number of severe urgency episodes (p< 0.001), number of urgency incontinence episodes (p=0.001), and number of nocturia episodes (p=0.002). There was a significant improvement in the OAB V8 score and treatment satisfaction (both p<0.001). Two mild treatment-related AEs were recorded. Both patients recovered without sequelae and completed the study. CONCLUSIONS: Peroneal eTNM® proved to be a highly effective and safe method for the home treatment of OAB, providing a therapeutic response in approximately 80% of patients.
Department of Surgical Studies Medical Faculty Ostrava University Ostrava Czech Republic
Department of Urology Odense University Hospital Odense Denmark
Department of Urology University Hospital Tř 17 Listopadu 1790 708 52 Ostrava Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23011325
- 003
- CZ-PrNML
- 005
- 20230801132951.0
- 007
- ta
- 008
- 230718s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00192-022-05359-3 $2 doi
- 035 __
- $a (PubMed)36125509
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Krhut, Jan $u Department of Urology, University Hospital, Tř. 17. Listopadu 1790, 708 52, Ostrava, Czech Republic. jan.krhut@fno.cz $u Department of Surgical Studies, Medical Faculty, Ostrava University, Ostrava, Czech Republic. jan.krhut@fno.cz $1 https://orcid.org/0000000342055926 $7 mzk2005309234
- 245 10
- $a Peroneal electrical transcutaneous neuromodulation in the home treatment of the refractory overactive bladder / $c J. Krhut, M. Rejchrt, M. Slovak, RV. Dvorak, M. Grepl, P. Zvara
- 520 9_
- $a INTRODUCTION AND HYPOTHESIS: The aim of this prospective, open-label, multicenter, noncomparative study was to evaluate the efficacy and safety of peroneal electrical transcutaneous neuromodulation (peroneal eTNM®) using the URIS® neuromodulation system as a home treatment for refractory overactive bladder (OAB). METHODS: The patients were treated with daily peroneal eTNM® for 30 min over a 6-week period. The primary endpoint was defined as the proportion of responders, i.e., participants with ≥ 50% reduction in the average daily sum of severe urgency episodes (defined as "I could not postpone voiding but had to rush to the toilet in order not to wet myself") and urgency incontinence episodes. In addition, bladder diary variables, symptom severity (OAB V8 questionnaire), treatment satisfaction (visual analog scale), and pain perception (visual analog scale) were evaluated at baseline (BL), at week 4 (W4), and at the end of treatment (EoT). Safety evaluations included monitoring of the incidence and severity of adverse events (AEs). Changes in time were analyzed using the nonparametric one-way ANOVA Friedman test for categorical variables and the Wilcoxon rank-sum test for the noncategorical variables. RESULTS: In total, 40 subjects were screened and 29 were included in the full analysis set. The proportion of responders was 86% at W4 and 79% at EoT. There was a significant reduction in frequency (p<0.001), number of severe urgency episodes (p< 0.001), number of urgency incontinence episodes (p=0.001), and number of nocturia episodes (p=0.002). There was a significant improvement in the OAB V8 score and treatment satisfaction (both p<0.001). Two mild treatment-related AEs were recorded. Both patients recovered without sequelae and completed the study. CONCLUSIONS: Peroneal eTNM® proved to be a highly effective and safe method for the home treatment of OAB, providing a therapeutic response in approximately 80% of patients.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a hyperaktivní močový měchýř $x farmakoterapie $7 D053201
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a výsledek terapie $7 D016896
- 650 12
- $a inkontinence moči $7 D014549
- 650 _2
- $a močení $x fyziologie $7 D014554
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Rejchrt, Michal $u Department of Urology, 2nd Faculty of Medicine of Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Slovak, Martin $u STIMVIA®, Ostrava, Czech Republic
- 700 1_
- $a Dvorak, Roman V $u STIMVIA®, Ostrava, Czech Republic
- 700 1_
- $a Grepl, Michal $u Department of Urology, University Hospital, Tř. 17. Listopadu 1790, 708 52, Ostrava, Czech Republic $u Department of Surgical Studies, Medical Faculty, Ostrava University, Ostrava, Czech Republic
- 700 1_
- $a Zvara, Peter $u Biomedical Laboratory and Research Unit of Urology, Department of Clinical Research, University of Southern Denmark, Odense, Denmark $u Department of Urology, Odense University Hospital, Odense, Denmark
- 773 0_
- $w MED00002395 $t International urogynecology journal $x 1433-3023 $g Roč. 34, č. 6 (2023), s. 1253-1260
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36125509 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132948 $b ABA008
- 999 __
- $a ok $b bmc $g 1963623 $s 1197590
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 34 $c 6 $d 1253-1260 $e 20220920 $i 1433-3023 $m International urogynecology journal $n Int. urogynecol. j. (Print) $x MED00002395
- LZP __
- $a Pubmed-20230718